Prolonged survival after splenectomy in Wiskott-Aldrich syndrome: a case report
Tóm tắt
Wiskott-Aldrich syndrome is a rare X-linked immunodeficiency disorder that is characterized by a variable clinical phenotype. Matched donor bone marrow transplantation is currently the only curative therapeutic option. We present the case of a 24-year-old male who was diagnosed at the age of seven with Wiskott-Aldrich syndrome. He did not respond to intravenous gammaglobulin and he experienced recurrent pulmonary infections despite prophylactic antibiotics. The patient had no matched donor. At the age of nine, he was submitted to splenectomy and his platelet count was normalized. Fifteen years later, the patient remains asymptomatic with a normal platelet count. He is still receiving prophylactic antibiotics and no bleeding episodes or septic complications have been reported. This case demonstrates that splenectomy can represent a safe therapeutic option in selected WAS patients, provided that there is a tight follow-up program, patient education and adherence to guidelines regarding post-splenectomy prophylaxis.
Tài liệu tham khảo
Ochs HD, Filipovich AH, Veys P, Cowan MJ, Kapoor N: Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant. 2009, 15: 84-90.
Wiskott A: Familiarer, angeborener morbus werlhofii?. Monatsschr Kinderbeilkd. 1937, 68: 212-216.
Aldrich RA, Steinberg AG, Campbell DC: Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea. Pediatrics. 1954, 13: 133-139.
Bouma G, Burns SO, Thrasher AJ: Wiskott-Aldrich Syndrome: Immunodeficiency resulting from defective cell migration and impaired immunostimulatory activation. Immunobiology. 2009, 214: 778-790. 10.1016/j.imbio.2009.06.009.
Albert MH, Bittner TC, Nonoyama S, Notarangelo LD, Burns S, Imai K, Espanol T, Fasth A, Pellier I, Strauss G: X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood. 2010, 115: 3231-3238. 10.1182/blood-2009-09-239087.
Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, Schulz A, Thrasher AJ, Mazzolari E, Slatter MA, Le DF, Blanche S, Veys P, Fasth A, Bredius R, Sedlacek P, Wulffraat N, Ortega J, Heilmann C, O'Meara A, Wachowiak J, Kalwak K, Matthes-Martin S, Gungor T, Ikinciogullari A, Landais P, Cant AJ, Friedrich W, Fischer A: Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood. 2008, 111: 439-445. 10.1182/blood-2007-03-076679.
Aiuti A, Roncarolo MG: Ten years of gene therapy for primary immune deficiencies. Hematology Am Soc Hematol Educ Program. 2009, 682-689.
Conley ME, Saragoussi D, Notarangelo L, Etzioni A, Casanova JL: An international study examining therapeutic options used in treatment of Wiskott-Aldrich syndrome. Clin Immunol. 2003, 109: 272-277. 10.1016/j.clim.2003.08.005.
Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA: A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994, 125: 876-885. 10.1016/S0022-3476(05)82002-5.
Zhu Q, Watanabe C, Liu T, Hollenbaugh D, Blaese RM, Kanner SB, Aruffo A, Ochs HD: Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood. 1997, 90: 2680-2689.
Lutskiy MI, Rosen FS, Remold-O'Donnell E: Genotype-proteotype linkage in the Wiskott-Aldrich syndrome. J Immunol. 2005, 175: 1329-1336.
Kobayashi R, Ariga T, Nonoyama S, Kanegane H, Tsuchiya S, Morio T, Yabe H, Nagatoshi Y, Kawa K, Tabuchi K, Tsuchida M, Miyawaki T, Kato S: Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Br J Haematol. 2006, 135: 362-366. 10.1111/j.1365-2141.2006.06297.x.
Pai SY, DeMartiis D, Forino C, Cavagnini S, Lanfranchi A, Giliani S, Moratto D, Mazza C, Porta F, Imberti L, Notarangelo LD, Mazzolari E: Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant. 2006, 38: 671-679. 10.1038/sj.bmt.1705512.
Mullen CA, Anderson KD, Blaese RM: Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases. Blood. 1993, 82: 2961-2966.
Cines DB, Bussel JB, McMillan RB, Zehnder JL: Congenital and acquired thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2004, 390-406.
Albert MH, Notarangelo LD, Ochs HD: Clinical spectrum, pathophysiology and treatment of the Wiskott-Aldrich syndrome. Curr Opin Hematol. 2010
Davies JM, Barnes R, Milligan D: Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clin Med. 2002, 2: 440-443.
Knutsen AP, Rosse WF, Kinney TR, Buckley RH: Immunologic studies before and after splenectomy in a patient with the Wiskott-Aldrich syndrome. J Clin Immunol. 1981, 1: 13-19. 10.1007/BF00915472.